DE

The Future Map · technological enabler · watchlist

Synthetic Antibodies

Readiness

TRL 5 · SRL 4.5 · gap +0.5

Gap = technical readiness − societal readiness. Positive: the technology is ready and society is not. Negative: society wants it more than the technology can deliver.

Source: WKO Innovation Map 26/27 (2026)

Not scored. Watchlist entries do not enter any gradient.

Laboratory-designed molecules that bind a chosen target the way an antibody does, engineered rather than raised in an animal or selected from an immune response.

The advantages over conventional monoclonals are practical: smaller molecules that reach tissue a full antibody cannot, better stability so the cold chain is less demanding, faster design cycles, and no animal step. Combined with the protein-design entry above, the design half of this is being compressed considerably.

Technical readiness 5 against societal readiness 4.5 — a rare case where the technology slightly leads acceptance, and the reason is that the clinical and regulatory apparatus is built around antibodies as a known class. A molecule that does the job differently is evaluated as a new thing, at new-thing cost and new-thing timelines.

Common misconception: that these replace monoclonal antibodies. They extend the approach to targets and conditions monoclonals cannot serve, which is a larger prize than substitution.

What it does

mechanism — not yet written. Published as missing rather than hidden.

Candidate megatrends — unreviewed

Unreviewed. Derived from this technology's WKO cluster, not from a judgement about this technology. A starting point for review, not a claim.

SDG: SDG 03. Good Health and Well-being · SDG 09. Industry, Innovation, and Infrastructure · SDG 10. Reducing Inequality


See it in the map →

Cite this entry

Talin, B. (2026). Synthetic Antibodies. The Future Map, dataset v0.4.0 (2026-09-07). https://futuremap.talin.digital/e/synthetic-antibodies/

Machine view: This entry as Markdown · The whole map as JSON

Updated 2026-09-07.